Merck halts trial after Keytruda-Lynparza combo flunks PhIII study in lung cancer
Katherine Lewin
News Reporter
Merck is halting a Phase III trial in non-small cell lung cancer (NSCLC) after its Keytruda-Lynparza combo flunked one of the primary endpoints in an interim data analysis.
In the KEYLYNK-008 trial, patients first got Keytruda (pembrolizumab) and chemotherapy, followed by Keytruda and Lynparza as a first-line treatment. But the data from the 857-patient trial did not show an improvement in overall survival, one of the study’s primary endpoints, compared to Keytruda and chemo followed by Keytruda plus a placebo. The other primary endpoint, progression-free survival, was also not statistically significant, though there was a “numerical improvement” compared to the placebo arm.
Time for immutep is coming
Merck halts trial after Keytruda-Lynparza combo flunks PhIII...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.040(11.9%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 33.0¢ | 28.0¢ | $7.278M | 23.75M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 53192 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 41048 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |